Market Feedback

Report
July 2024

© 2022. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Disclaimer

IQVIA is not an “authorised person” for the purposes of the Financial Services
and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry
on any other regulated activity under Part II of the FSMA 2000 (Regulated
Activities) Order 2001
The forecasts, projections, and related information contained herein are made
and provided subject to the assumptions, methodologies, caveats, and variables
described in this report and are based on third party sources and data
reasonably believed to be reliable. No warranty is made as to the completeness
or accuracy of such third-party sources or data
This report, in part or in whole, is not intended to constitute investment advice,
and is not a recommendation to purchase or not purchase, an endorsement of,
or an opinion as to the value of, any security or any investment instrument of any
entity
As with any attempt to estimate future events, the forecasts, projections,
conclusions, and other information included herein are subject to certain risks
and uncertainties, and are not to be considered guarantees of any particular
outcome
This report shall not be published, nor shall any public references to IQVIA be
made regarding these services or this report, without IQVIA’ prior written
approval. When so provided, this report and the information herein must always
be provided and used in its entirety, including this complete Disclaimer page
This report is subject to the IQVIA General Terms and Conditions.

1
Source: IQVIA TSA Dataset July'2024
IPM Key Highlights – July’24

IPM Growth and Monthly Sale Trend

21,000 20
16.5
15
11.2
10.5 10.1 10.3 10.5 9.8 10.1 9.8
9.0 8.8
20,000 11.5 7.6 7.6 10
8.6 7.9 7.7 7.4 7.4 8.0 5
6.4 5.8 6.7
5.1
3.5
19,000 1.3 0

-5

18,000 -10

-15

17,000 -20
Oct'23 18,986.0

June'24 17,730.0
July'23 17,816.5

Aug'23 18,700.9

Sept'23 19,173.8

Nov'23 18,002.3

Dec'23 18,066.8

Jan'24 17,937.5

Feb'24 17,970.2

Mar'24 17,387.6

Apr'24 19,534.2

May'24 18,915.4

July'24 19,883.2
-25

16,000 -30

Month Value'Cr Month growth MAT growth

• IPM monthly growth increased to 11.2% for July’24 from 6.7% reported
last month.
• MAT growth for July’24 was at 8%, which is higher than reported for last
four months.

Acute vs. Chronic Trend

270,000

60%
16.1%
220,000
10.6% 40%

7.9% 8.0%
5.7% 12.6%
170,000 20%
12.4%
18.2% 9.1% 10.0%
9.7%
9.6%
7.2% 6.7% 0%
3.4%
120,000

-20%

70,000
-40%
149039.8

109248.8

172999.3

186625.0

128309.8

206464.5

136966.4

222905.8
117075.6
92412.6

56627.1

63750.5

69549.4

78154.7

85939.4

20,000 -60%
MAT July'20 MAT July'21 MAT July'22 MAT July'23 MAT July'24
ACUTE CHRONIC OVERALL Acute growth Chronic Growth Overall Growth

• Chronic segment continued to grow faster @ 10% as compared to

Acute segment growth of 6.7% for MAT July’24.

Source: IQVIA TSA Dataset July'2024 2

 Monthly Growth Trends –July’24
IPM July month trend as compared to
preceding June month

22,000 40.0%

30.0%

18,000
20.0%
14.0% 14.0%
8.2%
10.2% 9.4%
12.1%
11.0% 10.0%
14,000 8.5% 6.1%
7.6% 9.3%
5.8% 6.1%
4.7% 0.0%
2.6%

10,000
-10.0%

-20.0%
6,000
13255.0

15377.2

10589.1

16740.5

11071.0

17877.5

12253.3

19883.2
-30.0%
8189.5

5065.5

9794.9

5582.3

6151.4

6806.5

7629.9
2,000 -40.0%
July'20 July'21 July'22 July'23 July'24

Acute Chronic Overall Acute Growth Chronic Growth Overall Growth

July month sale has always been higher than preceding June sale,
especially in acute segment. But July’24 growth has been the best in last 5
years as compared to preceding June, as shown in above chart.

IPM July month trend as compared to

July month of previous year

20,000.0 40.0%

18,000.0

19.6%
10.7% 20.0%
16,000.0 10.2% 12.1%
8.3% 16.0% 8.9%
11.2%
14,000.0 1.5% 6.8% 10.7%
10.2% 8.1%
4.6% 0.0%
-2.4%
12,000.0

10,000.0
-20.0%

8,000.0

6,000.0
-40.0%
13255.0

15377.2

10589.1

16740.5

11071.0

17877.5

12253.3

19883.2

4,000.0
8189.5

5065.5

9794.9

5582.3

6151.4

6806.5

7629.9

2,000.0 -60.0%
July'20 July'21 July'22 July'23 July'24
Acute Chronic Overall Acute Growth Chronic Growth Overall Growth

Chronic segment has grown faster @ 12.1% for month of July’24 as

compared to month of July’23. Acute segment grew by 10.7% for the same
period resulting in overall monthly growth of 11.2%.

Source: IQVIA TSA Dataset July'2024 3

Top Companies in IPM – July’24
RANKING MONTH July'24 MAT July'24
CORPORATIONS Values In Growth Values In Growth
MAT MON MS % MS % EVOL
Cr % Cr %
IPM 19883.22 100 11.22 222905.84 100 7.96 100
1 1 SUN* 1585.79 7.98 13.80 17332.76 7.78 9.28 101.22
2 2 ABBOTT* 1238.23 6.23 12.89 13841.59 6.21 8.81 100.79
3 3 CIPLA 1006.65 5.06 7.40 12161.25 5.46 7.14 99.24
4 4 MANKIND 864.24 4.35 13.83 9935.65 4.46 8.93 100.9
5 5 ALKEM* 794.21 3.99 8.01 8889.57 3.99 6.46 98.61
6 6 INTAS PHARMA* 745.78 3.75 18.38 8004.92 3.59 12.27 103.99
7 8 LUPIN LIMITED 697.14 3.51 13.51 7618.89 3.42 7.30 99.38
8 7 TORRENT PHARMA* 705.97 3.55 14.85 7600.37 3.41 8.59 100.58
9 9 MACLEODS PHARMA 631.91 3.18 6.23 7477.32 3.35 9.32 101.25
10 10 DR REDDYS LABS 621.23 3.12 12.21 6880.08 3.09 9.12 101.07
11 12 ARISTO PHARMA* 544.39 2.74 8.84 6444.03 2.89 7.76 99.81
12 11 ZYDUS CADILA* 568.85 2.86 13.53 6360.93 2.85 6.77 98.9
13 13 GLAXOSMITHKLINE* 450.83 2.27 4.49 5224.71 2.34 0.91 93.47
14 14 EMCURE* 445.25 2.24 6.09 5083.91 2.28 6.81 98.93
15 16 GLENMARK PHARMA 398.55 2.00 14.61 4653.82 2.09 11.29 103.08
16 15 IPCA LABS 433.34 2.18 23.76 4512.90 2.02 14.69 106.23
17 17 USV 379.32 1.91 8.51 4268.99 1.92 6.93 99.04
18 18 MICRO LABS* 308.12 1.55 9.49 3502.54 1.57 2.43 94.87
19 20 PFIZER* 267.89 1.35 2.24 3325.87 1.49 -1.52 91.22
20 19 ALEMBIC 271.07 1.36 6.45 3235.16 1.45 3.74 96.09
21 21 JB PHARMA* 235.07 1.18 11.84 2551.75 1.14 9.90 101.8
22 22 ERIS LIFESCIENCES* 210.53 1.06 9.96 2369.88 1.06 9.10 101.05
23 23 FDC 205.23 1.03 13.89 2367.70 1.06 9.58 101.49
24 24 SANOFI* 193.32 0.97 10.54 2291.03 1.03 5.60 97.81
25 25 HIMALAYA DRUG 159.48 0.80 12.54 1792.75 0.80 8.60 100.59
26 26 AJANTA PHARMA 158.11 0.80 16.22 1702.12 0.76 9.30 101.23
27 27 LA RENON HEALTHCA. 157.51 0.79 30.50 1599.17 0.72 19.48 110.67
28 28 CADILA PHARMA 135.45 0.68 2.56 1572.10 0.71 0.94 93.5
29 29 CORONA REMEDIES 127.93 0.64 17.38 1360.55 0.61 14.19 105.77
30 32 FRANCO INDIAN 112.54 0.57 -2.27 1320.65 0.59 -8.37 84.87
31 31 INDOCO* 117.33 0.59 9.47 1283.29 0.58 0.47 93.06
32 30 HETERO HEALTHCAR* 120.57 0.61 7.40 1282.13 0.58 10.22 102.09
33 35 BLUE CROSS 103.93 0.52 5.57 1223.53 0.55 -0.93 91.76
34 34 PROC.&GAMB.HEALTH 105.00 0.53 12.68 1150.78 0.52 -3.24 89.63
35 33 SYSTOPIC 105.88 0.53 13.94 1134.42 0.51 10.60 102.44
36 36 MEDLEY PHARMA 101.61 0.51 9.69 1045.95 0.47 4.87 97.13
37 37 WIN MEDICARE 87.78 0.44 10.31 967.17 0.43 5.19 97.43
38 39 FOURRTS INDIA 83.44 0.42 10.26 945.38 0.42 10.45 102.31
39 38 HEGDE & HEGDE 85.92 0.43 11.84 928.26 0.42 3.82 96.17
40 41 BHARAT SERUM 79.71 0.40 8.06 889.30 0.40 10.89 102.71

Source: IQVIA TSA Dataset July'2024 4

Top Brands in IPM – July’24
RANKING MONTH July'24 MAT July'24
MANU
PRODUCTS
MAT MON (Abbr.) Value'Cr MS % Growt Value'Cr MS Growth EVOL
h% % %
IPM 19883 100 11.22 222906 100 7.96 100
1 4 FORACORT CPL 67.20 0.34 4.09 884.14 0.40 14.65 106.2
2 3 MIXTARD ABT 68.33 0.34 -5.01 836.83 0.38 -4.76 88.22
3 1 AUGMENTIN GSK 72.45 0.36 3.93 825.25 0.37 1.68 94.18
4 2 GLYCOMET-GP USV 70.51 0.35 1.94 821.81 0.37 2.48 94.93
5 14 MONOCEF ATP 48.15 0.24 18.82 664.00 0.30 10.59 102.43
6 5 LIV-52 HIM 61.05 0.31 28.34 643.72 0.29 19.56 110.74
7 6 PAN A.K 60.28 0.30 9.10 637.94 0.29 12.27 103.99
8 8 THYRONORM ABT 55.19 0.28 8.25 627.87 0.28 6.20 98.37
9 12 CLAVAM A.K 51.16 0.26 3.50 606.87 0.27 -0.86 91.83
10 10 UDILIV SVY 54.27 0.27 26.01 600.42 0.27 24.97 115.75
11 7 ZERODOL-SP IPC 56.75 0.29 20.88 570.92 0.26 18.98 110.21
12 11 RYZODEG ABT 52.85 0.27 25.33 567.14 0.25 17.28 108.63
13 9 PAN-D A.K 54.63 0.27 23.55 563.25 0.25 17.75 109.07
14 15 LANTUS S.A 46.33 0.23 28.72 561.00 0.25 -3.32 89.55
15 13 BETADINE WMC 50.35 0.25 10.98 553.92 0.25 1.31 93.84
16 26 DUOLIN CPL 36.97 0.19 11.12 520.93 0.23 11.07 102.88
17 17 MANFORCE MA& 43.23 0.22 13.03 509.26 0.23 10.19 102.06
18 30 ELECTRAL FC8 35.04 0.18 17.21 497.48 0.22 20.29 111.42
19 21 TELMA GMK 40.33 0.20 11.21 490.52 0.22 18.20 109.48
20 52 BUDECORT CPL 28.75 0.14 2.99 480.71 0.22 12.58 104.28
21 16 ROSUVAS RBY 44.63 0.22 29.04 465.88 0.21 22.59 113.54
22 25 CALPOL GSK 37.33 0.19 2.58 461.27 0.21 -4.60 88.37
23 20 DEXORANGE F-I 42.46 0.21 -2.02 459.34 0.21 -0.41 92.24
24 32 AZITHRAL AMB 33.78 0.17 11.36 457.50 0.21 -2.13 90.65
25 19 SHELCAL TNT 42.59 0.21 22.47 456.60 0.20 6.74 98.87
26 22 ULTRACET JAN 39.92 0.20 8.85 426.18 0.19 5.54 97.76
27 27 DOLO MRB 36.72 0.18 18.04 422.47 0.19 -6.34 86.75
28 23 CILACAR JBH 38.50 0.19 16.02 415.06 0.19 18.66 109.9
29 28 LEVIPIL SPI 35.76 0.18 3.35 413.55 0.19 10.62 102.46
30 31 ACILOC CI6 34.01 0.17 1.07 413.54 0.19 3.22 95.61
31 29 ECOSPRIN-AV USV 35.34 0.18 11.79 401.23 0.18 10.03 101.91
32 39 DUPHASTON SVY 31.45 0.16 5.81 392.46 0.18 6.76 98.89
33 42 MOXIKIND-CV MA& 31.16 0.16 12.02 392.15 0.18 7.78 99.83
34 33 PANTOP ATP 32.72 0.16 10.40 382.19 0.17 14.01 105.6
35 41 TELMA-H GMK 31.21 0.16 13.70 375.34 0.17 25.88 116.6
36 43 NOVOMIX ABT 30.78 0.15 -5.83 372.36 0.17 -13.49 80.13
37 18 T-BACT GSK 42.82 0.22 20.04 368.49 0.17 -5.14 87.86
38 45 RANTAC JBH 30.20 0.15 -5.19 362.28 0.16 1.98 94.45
39 24 PREVENAR-13 PFZ 38.31 0.19 52.39 359.15 0.16 22.03 113.03
40 38 MIKACIN ATP 31.75 0.16 8.80 358.84 0.16 2.73 95.16

Source: IQVIA TSA Dataset July'2024 5

Top Therapeutic Class and Indian
Vs MNC Trend - July’24
Month July'24 MAT July'24
Rank Rank
Therapy Growth Growth
MAT Month Value 'Cr MS% Value 'Cr MS%
% %
IPM 19883.2 100.0% 11.2% 222905.8 100.0% 8.0%
1 1 CARDIAC 2531.2 12.7% 13.6% 28116.8 12.6% 10.7%
2 3 ANTI-INFECTIVES 2106.0 10.6% 13.7% 24941.8 11.2% 5.3%
3 2 GASTRO INTESTINAL 2273.8 11.4% 14.7% 23830.0 10.7% 9.5%
4 4 ANTI DIABETIC 1781.0 9.0% 11.1% 19685.3 8.8% 6.8%
5 8 RESPIRATORY 1300.9 6.5% 7.3% 17964.5 8.1% 2.1%
6 6 PAIN / ANALGESICS 1617.4 8.1% 10.9% 17738.9 8.0% 7.9%
7 5 VITAMINS/MINERALS/NUTRIENTS 1627.0 8.2% 11.6% 17429.5 7.8% 8.3%
8 7 DERMA 1426.2 7.2% 11.4% 15351.0 6.9% 6.9%
9 9 NEURO / CNS 1208.7 6.1% 12.3% 13358.2 6.0% 8.6%
10 10 GYNAEC. 999.2 5.0% 4.2% 11077.8 5.0% 5.9%
11 11 ANTINEOPLAST/IMMUNOMODULATOR 523.9 2.6% 13.1% 5746.0 2.6% 21.5%
12 12 UROLOGY 448.1 2.3% 15.2% 4846.9 2.2% 13.5%
13 13 OPHTHAL / OTOLOGICALS 389.1 2.0% -7.7% 4331.2 1.9% 4.1%
14 15 HORMONES 288.3 1.5% 5.7% 3445.8 1.5% 6.0%
15 14 VACCINES 289.1 1.5% 7.9% 3253.7 1.5% 13.9%
16 16 HEPATOPROTECTIVES 251.1 1.3% 17.9% 2694.3 1.2% 16.8%
17 17 BLOOD RELATED 180.4 0.9% 9.3% 1989.2 0.9% 5.8%
18 18 STOMATOLOGICALS 161.2 0.8% 11.7% 1744.7 0.8% 8.6%
19 19 ANTIVIRAL 99.0 0.5% -6.3% 1188.3 0.5% 5.5%
20 20 PARENTERAL 57.9 0.3% 16.5% 671.3 0.3% 18.7%

• Anti-infective was the key driver for high monthly growth as the monthly growth
was higher than its MAT growth by 8.4%. Opthal/Otological therapy and Anti-
Viral therapy pulled down the monthly growth as the monthly growth was
considerably lower than their respective MAT growth.
• 13 Therapies out of top 20 reported higher growth for the month of July’24 as
compared to their respective MAT growth for the same period.
Indian_MNC Trend
200000 28%

18.8%
16.8% 20%
160000 13.5% 12.8%
10.1% 10.1% 10.1% 11.1%
15.5% 7.6% 8.5% 8.2% 12%
7.0% 12.7%
120000
9.9% 9.0%
7.1% 8.0% 8.1% 4%
5.4% 6.6%
5.3% 4.1% 4.9%
80000
-4%
106,611

114,118

142,986

155,145

172,434

186,620

40000
19,229

58,328
90,020

96,816
20,259

21,699

22,848

52,966
10,784

11,221

65,823
12,332

72,501
13,438

30,013

31,480

34,031

36,286

-12%

0 -20%
MAT July'23
MAT July'21

MAT July'22

MAT July'23

MAT July'24

MAT July'21

MAT July'22

MAT July'24

MAT July'21

MAT July'22

MAT July'23

MAT July'24

ACUTE CHRONIC Overall

Indian MNC Indian Growth % MNC Growth %

Growth of MNC companies remained lower than Indian companies for both
Acute and Chronic segments but it is constantly catching up in both the
segments as shown in above chart.

Source: IQVIA TSA Dataset July'2024 6

Top NI in IPM last 12 months-
July’24
MAT
Rank BRANDS COMPANY SUPERGROUP
July'24'Cr

TOTAL NI VALUE 1274.7

1 CODISTAR-NF MANKIND RESPIRATORY 38.1
2 PHENSEDYL ABBOTT* RESPIRATORY 36.2
3 ENHERTU ASTRAZENECA ANTINEOP./IMMUNOMODU. 33.3
4 REJUNEX-CD3 NF INTAS* VITAMINS/MINERALS/NUTRIENTS 22.7
5 VORXAR TORRENT* CARDIAC 16.8
6 LINVAS LUPIN CARDIAC 13.3
7 TYVALZI SUN* NEURO / CNS 11.8
8 EFFCM DRL GYNAEC. 11.5
9 GEMER SITA SUN* ANTI DIABETIC 10.4
10 RYBREVANT J&J ANTINEOP./IMMUNOMODU. 9.9
11 HEXASIIL SERUM INSTITUTE VACCINES 9.5
12 ONDERO-D LUPIN ANTI DIABETIC 9.4
13 NEW GRILINCTUS FRANCO INDIAN RESPIRATORY 9.2
14 RESPIRA + GENO RESPIRATORY 9.2
15 MYORIL MAXX CORONA REMEDIES PAIN / ANALGESICS 9.1
16 RICHAR FCM ALEMBIC GYNAEC. 8.9
17 SUMO ACE ALKEM* PAIN / ANALGESICS 8.4
18 VITCOFOL-FCM FDC GYNAEC. 8.3
19 ALBUHIGH BDR PHARMA PARENTERAL 8.1
20 INSUQUICK USV ANTI DIABETIC 8.1

• 3396 brands were launched in last 12 months clocking a sale of 1274.7

Cr.
• Brands launched in last 12 months contributed 0.6% to IPM and 7.6%
to IPM growth for MAT July’24.
• Mankind grossed the highest sales of 87.5 Cr from 49 brands, followed
by Intas @ 63.8 Cr with 38 brands and Abbott*@ 61.4 Cr from 46
brands.
• Among the brands launched in last 12 months, Antidiabetic reported
the highest value of 168.1 Cr from 550 brands, followed by Respiratory
with 151.5 Cr from 245 brands and Gynaec. with a sale of 143.9 Cr
from 221 brands.
• Highest number of brands were launched in Anti-Diabetic,
Vitamin/Minerals/Nutrients and Cardiac segment.

Source: IQVIA TSA Dataset July'2024 7

Performance of Top 30 Metros in
IPM – July’24
MAT July'23 MAT July'24 MAT July'23 MAT July'24

Rank Metro Rank Metro

Value’ Growth Value’ Growth Value’ Growth Value’ Growth
Cr % Cr % Cr % Cr %

1 DELHI 9,258 21 % 10,263 11 % 17 KOCHI 1,064 16 % 1,151 8%

2 MUMBAI 8,074 3% 8,503 5% 18 KANPUR 1,102 8% 1,150 4%

3 CALCUTTA 7,795 12 % 8,224 5% 19 LUDHIANA 1,075 12 % 1,150 7%

4 HYDERABAD 6,159 17 % 6,738 9% 20 SURAT 1,117 16 % 1,145 3%

5 BANGALORE 4,962 20 % 5,293 7% 21 VIJAYWADA 997 12 % 1,079 8%

6 CHENNAI 4,310 9% 4,669 8% 22 MADURAI 859 12 % 942 10 %

7 PUNE 2,639 17 % 3,000 14 % 23 BHOPAL 815 17 % 924 13 %

8 LUCKNOW 2,587 9% 2,814 9% 24 NASIK 741 2% 878 18 %

9 AHMEDABAD 2,242 14 % 2,569 15 % 25 VADODARA 755 10 % 765 1%

10 PATNA 1,950 16 % 2,021 4% 26 ALLAHABAD 683 9% 728 7%

11 JAIPUR 1,861 8% 1,937 4% 27 MEERUT 651 12 % 704 8%

12 AGRA 1,414 13 % 1,630 15 % 28 JABALPUR 660 6% 687 4%

13 VARANASI 1,448 5% 1,554 7% 29 VIZAG 610 7% 627 3%

14 COIMBATORE 1,221 16 % 1,352 11 % 30 ASANSOL 386 8% 403 5%

15 NAGPUR 1,224 13 % 1,332 9% Grand Total 69,746 12.8 % 75,383 8.1 %

16 INDORE 1,086 21 % 1,151 6%

• Top 30 cities by market size mentioned in the above table grew slightly
faster @ 8.1% as compared to overall growth of 8% for MAT July’24.
• Top 30 metros in India contributed to 33.8% to IPM Sales for MAT
July’24, which is slightly higher than 33.7% reported last month.
• Nashik , Agra, Ahmedabad, Pune and Bhopal were the fastest growing
markets among the Top 30 metros for MAT July’24 in the same order.
While the top 3 were the same last month also, Pune has overtaken
Bhopal to come at 4th spot.
• 15 out of 30 Top metros grew faster than IPM while 14 metros grew
slower than the IPM growth of 8% for MAT July’24.
• Among the 6 mega metros, Delhi remained the fastest growing @10.9%
for MAT July’24, followed by Hyderabad @9.4% and Chennai @8.3%.

Source: IQVIA TSA Dataset July'2024 8

Regional Performance in IPM-MAT
July’24
Values
Zone State MS % Growth %
Crores
North UTTAR PRADESH 25,039.1 41 % 8.7 %
DELHI 10,263.2 17 % 10.9 %
RAJASTHAN 9,001.9 15 % 3.4 %
PUNJAB 7,231.4 12 % 10.0 %
HARYANA 4,684.2 8% 8.3 %
JAMMU & KASHMIR 2,656.8 4% 8.8 %
UTTARAKHAND 1,615.8 3% 7.1 %
HIMACHAL PRADESH 677.0 1% 7.6 %
North Zone 61,169.4 27 % 8.3 %
South KARNATAKA 13,178.6 22 % 5.7 %
TAMILNADU 11,206.2 19 % 9.1 %
TELANGANA 11,151.2 19 % 9.1 %
KERALA 10,752.2 18 % 6.0 %
ANDHRA PRADESH 8,242.6 14 % 3.6 %
CHENNAI 4,668.8 8% 8.3 %
South Zone 59,199.7 27 % 6.9 %
East WEST BANGAL 14,241.4 26 % 9.8 %
BIHAR 11,719.4 21 % 7.5 %
KOLKATA 8,223.5 15 % 5.5 %
ASSAM 7,508.6 14 % 8.2 %
ORISSA 7,222.5 13 % 9.3 %
JHARKHAND 3,254.0 6% 10.2 %
CHATTISGARH 2,820.5 5% 10.8 %
East Zone 54,989.8 25 % 8.4 %
West MAHARASHTRA 19,139.4 40 % 9.1 %
MADHYA PRADESH 9,776.9 21 % 9.7 %
GUJARAT 9,488.8 20 % 8.3 %
MUMBAI 8,502.6 18 % 5.3 %
GOA 639.3 1% 6.6 %
West Zone 47,547.0 21 % 8.3 %
IPM 222,905.8 100 % 8.0 %

• Uttar Pradesh is the largest market in India contributing 11.2% to IPM

and 41% to North Zone followed by Maharashtra contributing 8.6% and
West Bengal contributing 6.4% to IPM.
• Delhi is the fastest growing State growing by 10.9% followed by
Chattisgarh growing at 10.8%, Jharkhand at 10.2%, and Punjab @ 10%
for MAT July’24.

Source: IQVIA TSA Dataset July'2024 9

Zonal fastest growing among the
Top 50 companies- MAT July’24
Fastest Growing West Zone Fastest Growing South Zone
Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 ASTRAZENECA 208 38.4 % MERCK SPECIALITIES 303 39.9 %
2 RELIANCE LIFESCIE. 247 23.1 % EAST WEST PHARMA 278 30.1 %
3 LA RENON HEALTHCA. 385 20.3 % LA RENON HEALTHCA. 482 24.8 %
4 PHARMED 174 18.2 % JANSSEN 334 22.5 %
5 UNISON PHARMA 320 15.8 % ASTRAZENECA 250 18.6 %
6 SYSTOPIC 222 14.9 % IPCA LABS 1,017 16.9 %
7 SAMARTH PHARMA 201 14.3 % SAMARTH PHARMA 251 16.1 %
8 TROIKAA PHARMA 196 13.2 % CORONA REMEDIES 236 15.9 %
9 IPCA LABS 957 13.0 % GLENMARK PHARMA 1,510 15.5 %
10 MANKIND 2,306 12.3 % INTAS PHARMA* 1,815 12.5 %
11 ABBOTT* 2,960 12.1 % AJANTA PHARMA 439 12.2 %
12 CORONA REMEDIES 597 11.8 % ICON LIFESCIENCES 210 11.8 %
13 INTAS PHARMA* 1,714 11.6 % BHARAT SERUM 254 11.4 %
14 ERIS LIFESCIENCES* 571 11.3 % SYSTOPIC 354 9.6 %
15 MACLEODS PHARMA 1,538 10.7 % FOURRTS INDIA 507 9.3 %
16 JB PHARMA* 473 10.2 % CIPLA 3,268 8.4 %
17 ZYDUS CADILA* 1,291 9.6 % ERIS LIFESCIENCES* 751 8.3 %
18 TORRENT PHARMA* 1,616 9.5 % HETERO HEALTHCARE* 417 7.8 %
19 ARISTO PHARMA* 1,078 9.4 % SUN* 5,819 7.8 %
20 DR REDDYS LABS 1,467 9.3 % JB PHARMA* 689 7.5 %

Fastest Growing North Zone Fastest Growing East Zone

Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 ASTRAZENECA 266 35.7 % CORONA REMEDIES 237 23.0 %
2 BAYER PHARMA LTD. 166 33.4 % FOURRTS INDIA 202 18.6 %
3 SAMARTH PHARMA 240 19.9 % LA RENON HEALTHCA. 359 17.4 %
4 MYLAN PHARMA 231 19.5 % FDC 291 15.5 %
5 IPCA LABS 1,384 19.0 % HETERO HEALTHCARE* 212 13.5 %
6 HETERO HEALTHCARE* 170 18.0 % MACLEODS PHARMA 2,459 13.1 %
7 MARTIN HARRIS 192 16.2 % SUN* 4,813 12.4 %
8 BIOCON 188 15.6 % JB PHARMA* 632 12.1 %
9 HIMALAYA DRUG 682 15.6 % GLENMARK PHARMA 1,141 11.2 %
10 DR REDDYS LABS 1,727 14.6 % INTAS PHARMA* 1,934 11.1 %
11 LA RENON HEALTHCA. 373 14.3 % EAST INDIA 172 11.0 %
12 BHARAT SERUM 271 14.1 % TORRENT PHARMA* 1,964 10.3 %
13 INTAS PHARMA* 2,543 13.5 % MANKIND 1,922 10.0 %
14 EMCURE* 1,162 12.0 % MEYER ORGANICS 249 9.8 %
15 CORONA REMEDIES 290 11.3 % ABBOTT* 3,081 9.8 %
16 AJANTA PHARMA 384 11.1 % IPCA LABS 1,155 9.4 %
17 FDC 910 10.7 % ZYDUS CADILA* 1,551 9.3 %
18 JB PHARMA* 757 10.2 % SYSTOPIC 251 9.1 %
19 ERIS LIFESCIENCES* 654 10.1 % BHARAT SERUM 177 8.7 %
20 SYSTOPIC 309 10.0 % AJANTA PHARMA 515 8.5 %

Source: IQVIA TSA Dataset July'2024

10
Zonal fastest growing among the
Top 51-100 companies- MAT
July’24
Fastest Growing West Zone Fastest Growing South Zone
Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 NATCO PHARMA 107 43.0 % MSN LABS 99 72.7 %
2 MSN LABS 105 36.4 % BRISTOL-MYER SQUIB 63 69.7 %
3 CELON LAB 75 34.2 % KEPLER HEALTHCARE 74 42.1 %
4 GALDERMA 109 28.4 % FRESENIUS KABI 171 34.2 %
5 BDF 113 27.0 % NUTRICIA INTERNAT 135 24.9 %
6 ICON LIFESCIENCES 68 23.8 % BRINTON PHARMA 81 24.8 %
7 BIOLOGICAL E 83 21.2 % MARTIN HARRIS 73 23.2 %
8 BAYER PHARMA LTD. 92 20.7 % BAYER PHARMA LTD. 100 22.7 %
9 KHANDELWAL 74 20.5 % NATCO PHARMA 136 19.9 %
10 SERVIER INDIA 126 17.2 % KLM LABS 148 19.6 %
11 MERCK SPECIALITIES 121 16.2 % TROIKAA PHARMA 140 19.4 %
12 NEON LABS 133 15.1 % RPG LIFE SCIENCES 147 17.7 %
13 SERUM INSTITUTE 118 14.7 % ELI LILLY 76 16.1 %
14 NUTRICIA INTERNAT 149 14.4 % LINUX LAB 137 15.8 %
15 KLM LABS 102 13.0 % ENTOD 132 15.7 %
16 PIRAMALHEALTHCARE* 85 12.1 % JUGGAT PHARMA 109 12.8 %
17 UNIMED TECHNOLOGIE 67 11.6 % PIRAMALHEALTHCARE* 71 12.7 %
18 OVERSEAS 87 10.9 % UNIMED TECHNOLOGIE 151 11.7 %
19 ENTOD 115 10.7 % BAYER ZYDUS PHARMA 144 11.3 %
20 RAPTAKOS BRETT 148 10.3 % GUFIC 169 10.4 %

Fastest Growing North Zone Fastest Growing East Zone

Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 TAKEDA PHARMA 86 130.5 % NUTRICIA INTERNAT 139 32.5 %
2 ELI LILLY 118 83.0 % NEON LABS 100 28.1 %
3 NATCO PHARMA 136 50.1 % ALTEUS BIOGENICS 109 26.1 %
4 MSN LABS 150 34.5 % MERCK SPECIALITIES 128 25.3 %
5 MERCK SPECIALITIES 102 28.8 % GALDERMA 68 24.6 %
6 ALCON 68 27.2 % MYLAN PHARMA 74 21.3 %
7 NUTRICIA INTERNAT 155 26.2 % ASTRAZENECA 103 21.1 %
8 KHANDELWAL 113 23.2 % NATCO PHARMA 151 18.4 %
9 AAREEN HEALTHCARE 150 23.1 % UNIMED TECHNOLOGIE 76 18.0 %
10 TROIKAA PHARMA 163 21.7 % TROIKAA PHARMA 72 17.3 %
11 PIRAMALHEALTHCARE* 89 21.3 % SERVIER INDIA 96 15.8 %
12 MOREPEN LABS 73 20.0 % AGLOWMED 96 15.2 %
13 OVERSEAS 129 20.0 % TABLETS INDIA 156 15.0 %
14 RPG LIFE SCIENCES 140 18.3 % RELIANCE LIFESCIE. 103 14.1 %
15 GALDERMA 83 17.6 % RPG LIFE SCIENCES 79 13.6 %
16 TAS MED 80 16.4 % CAPLET INDIA 68 13.6 %
17 AKUMENTIS HEALTH 126 15.7 % OZONE 105 13.4 %
18 EAST INDIA 95 15.2 % BAYER PHARMA LTD. 84 12.5 %
19 UNIMED TECHNOLOGIE 88 14.4 % BAYER ZYDUS PHARMA 72 12.3 %
20 SERVIER INDIA 119 13.6 % MARTIN HARRIS 148 11.1 %

Source: IQVIA TSA Dataset July'2024 11

 East Zone Top Companies- MAT
July’24
ASSAM Bihar
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 ABBOTT* 509.7 11 % ALKEM* 1,168.7 5%
2 ALKEM* 494.0 7% ARISTO PHARMA* 1,153.8 5%
3 SUN* 481.2 12 % MACLEODS PHARMA 840.4 19 %
4 ALEMBIC 459.6 7% SUN* 709.9 15 %
5 LUPIN LIMITED 411.4 6% ABBOTT* 609.4 10 %
6 EMCURE* 272.7 3% CIPLA 420.1 10 %
7 CIPLA 261.4 5% LUPIN LIMITED 371.6 11 %
8 INTAS PHARMA* 260.1 17 % INTAS PHARMA* 366.9 9%
9 DR REDDYS LABS 235.0 14 % MANKIND 363.3 11 %
10 GLAXOSMITHKLINE* 212.3 8% ZYDUS CADILA* 290.9 8%
11 MACLEODS PHARMA 196.2 8% GLAXOSMITHKLINE* 262.4 1%
12 ZYDUS CADILA* 193.6 14 % MICRO LABS* 252.6 8%
13 GLENMARK PHARMA 180.0 14 % ALEMBIC 244.1 8%
14 MANKIND 176.0 6% TORRENT PHARMA* 242.1 17 %
15 TORRENT PHARMA* 174.9 11 % IPCA LABS 225.8 13 %
16 IPCA LABS 148.2 4% DR REDDYS LABS 215.5 -9 %
17 PFIZER* 127.2 14 % PFIZER* 178.6 1%
18 ARISTO PHARMA* 119.5 3% EMCURE* 176.2 -0 %
19 LA RENON HEALTHCA. 109.6 18 % FRANCO INDIAN 159.8 -18 %
20 USV 96.6 1% CADILA PHARMA 158.6 -4 %
Chattisgarh Jharkhand
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 MANKIND 210.3 13 % ALKEM* 239.8 5%
2 SUN* 178.9 15 % ABBOTT* 213.8 13 %
3 ABBOTT* 171.8 4% MACLEODS PHARMA 206.3 11 %
4 MACLEODS PHARMA 131.1 8% ARISTO PHARMA* 172.5 7%
5 LUPIN LIMITED 105.5 15 % MANKIND 155.3 12 %
6 DR REDDYS LABS 97.8 19 % SUN* 152.7 16 %
7 ZYDUS CADILA* 92.5 4% LUPIN LIMITED 129.2 15 %
8 CIPLA 80.5 3% CIPLA 127.5 10 %
9 ARISTO PHARMA* 77.8 14 % DR REDDYS LABS 116.4 16 %
10 ALKEM* 70.7 17 % IPCA LABS 107.3 14 %
11 GLAXOSMITHKLINE* 67.4 4% TORRENT PHARMA* 94.3 -0 %
12 INTAS PHARMA* 67.1 10 % GLAXOSMITHKLINE* 69.9 4%
13 TORRENT PHARMA* 61.3 2% INTAS PHARMA* 64.5 12 %
14 IPCA LABS 56.0 13 % ALEMBIC 62.1 8%
15 FDC 46.6 -0 % USV 57.6 15 %
16 EMCURE* 43.8 5% ZYDUS CADILA* 47.9 8%
17 ERIS LIFESCIENCES* 43.6 10 % GLENMARK PHARMA 47.4 13 %
18 USV 41.4 14 % PFIZER* 46.5 12 %
19 GLENMARK PHARMA 41.2 48 % EMCURE* 46.3 4%
20 PFIZER* 39.2 10 % MICRO LABS* 43.2 8%
Orissa West Bengal Kolkata
Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 MACLEODS PHARMA 459.4 15 % SUN* 2,200.5 17 % SUN* 750.2 1%
2 MANKIND 433.1 8% ALKEM* 1,028.2 8% TORRENT PHARMA* 587.4 10 %
3 ABBOTT* 432.9 14 % ABBOTT* 782.3 9% INTAS PHARMA* 416.7 10 %
4 ALKEM* 407.9 9% CIPLA 585.6 7% LUPIN LIMITED 412.9 0%
5 INTAS PHARMA* 345.8 12 % TORRENT PHARMA* 558.7 16 % DR REDDYS LABS 398.9 4%
6 SUN* 339.9 5% LUPIN LIMITED 494.8 13 % ALKEM* 370.8 5%
7 ARISTO PHARMA* 284.4 9% ZYDUS CADILA* 490.7 7% ABBOTT* 360.5 6%
8 TORRENT PHARMA* 245.1 -1 % GLAXOSMITHKLINE* 472.9 5% CIPLA 265.5 -1 %
9 CIPLA 240.9 12 % INTAS PHARMA* 412.6 11 % MACLEODS PHARMA 240.9 5%
10 ZYDUS CADILA* 221.6 22 % DR REDDYS LABS 407.9 13 % EMCURE* 228.3 9%
11 DR REDDYS LABS 190.4 9% MACLEODS PHARMA 384.8 10 % GLENMARK PHARMA 219.5 1%
12 GLENMARK PHARMA 179.2 15 % MANKIND 374.3 13 % ZYDUS CADILA* 213.7 4%
13 IPCA LABS 171.7 10 % GLENMARK PHARMA 330.8 12 % IPCA LABS 210.2 11 %
14 LUPIN LIMITED 165.4 10 % ARISTO PHARMA* 312.8 8% MANKIND 209.5 8%
15 ALEMBIC 151.4 5% ALEMBIC 282.2 6% JB PHARMA* 194.3 12 %
16 U S V 149.9 9% EMCURE* 278.9 2% PFIZER* 187.4 -0 %
17 EMCURE* 136.2 4% IPCA LABS 236.0 5% SANOFI* 149.4 13 %
18 MICRO LABS* 99.5 11 % JB PHARMA* 193.1 8% GLAXOSMITHKLINE* 136.4 0%
19 AJANTA PHARMA 89.0 12 % WALLACE* 169.4 9% USV 134.4 -0 %
20 ERIS LIFESCIENCES* 85.8 1% USV 155.8 5% AJANTA PHARMA 106.8 3%

Source: IQVIA TSA Dataset July'2024 12

East Zone Top Brands- MAT
July’24
Assam Bihar
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 PAN ALKEM* 55.8 11 % MONOCEF ARISTO* 104.7 5%
2 LIV-52 HIMALAYA 41.9 13 % CLAVAM ALKEM* 93.9 -1 %
3 UDILIV ABBOTT* 37.0 18 % MONTAZ ARISTO* 80.3 10 %
4 PAN-D ALKEM* 36.0 14 % XONE ALKEM* 72.0 2%
5 TELLZY-AM ALEMBIC 34.9 25 % ACILOC CADILA 67.0 -10 %
6 AZITHRAL ALEMBIC 34.4 2% ELECTRAL FDC 64.5 33 %
7 CLAVAM ALKEM* 34.4 -7 % DEXORANGE FRANCO 63.9 -3 %
8 THYRONORM ABBOTT* 32.6 22 % PANTOP-D ARISTO* 61.9 -10 %
9 ELECTRAL FDC 30.6 10 % AZITHRAL ALEMBIC 61.8 7%
10 MIXTARD ABBOTT* 28.5 -1 % MONOCEF-SB ARISTO* 60.4 4%
11 RYZODEG ABBOTT* 28.1 33 % MIKACIN ARISTO* 57.4 -1 %
12 BEVON EMCURE* 26.3 4% ZERODOL-SP IPCA 52.6 4%
13 TELLZY ALEMBIC 25.8 13 % PAN ALKEM* 51.3 26 %
14 RABLET-D LUPIN 25.1 11 % A TO Z NS ALKEM* 50.6 -9 %
15 BETADINE WIN MEDI. 21.9 -3 % LIV-52 HIMALAYA 49.9 14 %
16 GLYCOMET-GP USV 21.4 0% TRAXOL ALKEM* 48.6 8%
17 NOVOMIX ABBOTT* 20.8 -3 % TRAXOL-S ALKEM* 46.7 12 %
18 T-BACT GSK* 20.5 2% TAXIM-O ALKEM* 44.9 5%
19 BETNOVATE-N GSK* 20.5 81 % ODICEF GALPHA 43.7 0%
20 BETNOVATE-C GSK* 20.4 22 % PANTOP ARISTO* 42.7 13 %
Chattisgarh Jharkhand
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MANFORCE MANKIND 31.4 8% RYZODEG ABBOTT* 20.4 51 %
2 AMLOKIND-AT MANKIND 11.2 22 % BETADINE WIN MEDI. 19.6 2%
3 BETADINE WIN MEDI. 11.0 9% ELECTRAL FDC 18.4 23 %
4 ELECTRAL FDC 10.6 29 % CLAVAM ALKEM* 17.9 -6 %
5 RYZODEG ABBOTT* 10.2 7% MIXTARD ABBOTT* 17.8 0%
6 BETNOVATE-C GSK* 10.0 -13 % ALBUREL RELIANCE LIFE. 16.5 5%
7 ACILOC CADILA 9.9 21 % MANFORCE MANKIND 16.4 5%
8 GLYCOMET-GP USV 9.7 6% RAPITHER-AB IPCA 16.3 31 %
9 MONOCEF ARISTO* 9.6 27 % XONE ALKEM* 16.2 -8 %
10 ZINCOVIT APEX 8.6 5% ZERODOL-SP IPCA 15.3 8%
11 MOXIKIND-CV MANKIND 8.6 23 % AZITHRAL ALEMBIC 13.5 6%
12 ZERODOL-SP IPCA 8.5 20 % TAXIM-O ALKEM* 13.2 -12 %
13 DEXORANGE FRANCO 8.2 -5 % UDILIV ABBOTT* 12.8 23 %
14 MIXTARD ABBOTT* 8.1 -9 % ACILOC CADILA 12.6 37 %
15 AZITHRAL ALEMBIC 8.0 15 % PAN ALKEM* 12.1 12 %
16 DEXOLAC NUTRICIA 8.0 109 % DEXOLAC NUTRICIA 12.1 111 %
17 PANDERM ++ MACLEODS 7.9 -3 % CRESP DRL 12.0 65 %
18 LIV-52 HIMALAYA 7.9 7% THYROX MACLEODS 11.7 10 %
19 LEVIPIL SUN* 7.8 22 % XONE-XP ALKEM* 11.6 19 %
20 ZIFI FDC 7.4 -2 % MIKACIN ARISTO* 11.1 -3 %
Orissa West Bengal Kolkata
Rank Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
1 MIXTARD ABBOTT* 46.2 7% PAN-D ALKEM* 127.8 14 % PAN-D ALKEM* 57.5 24 %
2 LACTODEX RAPTAKOS 44.7 14 % PAN ALKEM* 109.7 5% SHELCAL TORRENT * 55.4 63 %
3 GLYCOMET-GP U S V 44.2 10 % CLAVAM ALKEM* 105.1 -3 % PAN ALKEM* 54.7 13 %
4 MANFORCE MANKIND 36.9 6% AUGMENTIN GSK* 82.6 8% CILACAR JB * 42.7 25 %
5 CLAVAM ALKEM* 32.8 -3 % MOXCLAV SUN* 79.8 18 % TELMA GLENMARK 39.2 3%
6 PAN ALKEM* 31.4 18 % CALPOL GSK* 77.0 -2 % OMEZ DRL 39.1 12 %
7 UDILIV ABBOTT* 25.9 44 % AZITHRAL ALEMBIC 75.3 -4 % LANTUS SANOFI* 39.0 10 %
8 ASCORIL-LS GLENMARK 24.7 17 % T-BACT GSK* 63.8 0% JANUMET MSD* 36.5 33 %
9 PANTOP-D ARISTO* 23.9 -8 % FORACORT CIPLA 63.4 17 % RANTAC JB * 36.3 -13 %
10 ZERODOL-SP IPCA 23.1 -3 % RANTAC JB * 58.2 1% CILACAR-T JB * 33.0 36 %
11 CHERI ALKEM* 22.1 24 % PANTOCID-D SUN* 52.2 18 % CHYMORAL TORRENT * 32.6 78 %
12 AZITHRAL ALEMBIC 20.2 -8 % DUOLIN CIPLA 46.8 5% NEXPRO-RD TORRENT * 30.2 71 %
13 PAN-D ALKEM* 19.7 20 % ROSUVAS SUN* 45.6 39 % ZERODOL-SP IPCA 30.0 35 %
14 CYRA-D SYSTOPIC 18.8 -8 % VOLINI SUN* 44.7 3% RYZODEG ABBOTT* 28.7 3%
15 PANTOP ARISTO* 18.3 11 % TELMA GLENMARK 42.6 23 % CRESP DRL 28.1 49 %
16 UNWANTED-KIT MANKIND 17.7 2% SPORIDEX SUN* 41.7 17 % MIXTARD ABBOTT* 27.2 13 %
17 FORACORT CIPLA 17.7 10 % UDILIV ABBOTT* 41.7 20 % BETADINE WIN MEDI. 26.4 -10 %
18 THYROX MACLEODS 17.4 16 % ELTROXIN GSK* 40.6 11 % ROSUVAS SUN* 23.4 -1 %
19 MONTEK-LC SUN* 17.0 8% TAXIM-O ALKEM* 39.6 2% CLAVAM ALKEM* 22.7 -8 %
20 O2 MEDLEY 16.6 -4 % ASCORIL-LS GLENMARK 39.3 5% FORACORT CIPLA 22.4 12 %

Source: IQVIA TSA Dataset July'2024 13

North Zone Top Companies- MAT
July’24
Delhi Haryana
Rank
Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 954.0 12 % CIPLA 546.1 5%
2 ABBOTT* 747.7 17 % ABBOTT* 358.5 10 %
3 INTAS PHARMA* 675.3 24 % SUN* 332.4 6%
4 CIPLA 604.1 7% INTAS PHARMA* 252.4 27 %
5 DR REDDYS LABS 411.0 7% LUPIN LIMITED 222.5 8%
6 LUPIN LIMITED 346.2 5% MANKIND 190.6 14 %
7 TORRENT PHARMA* 327.8 11 % ZYDUS CADILA* 167.4 9%
8 GLAXOSMITHKLINE* 287.0 8% GLAXOSMITHKLINE* 126.4 -2 %
9 MANKIND 276.6 13 % TORRENT PHARMA* 124.5 1%
10 ALKEM* 276.5 5% DR REDDYS LABS 116.7 25 %
11 EMCURE* 274.6 24 % MACLEODS PHARMA 114.9 4%
12 ZYDUS CADILA* 255.3 -7 % GLENMARK PHARMA 99.9 12 %
13 PFIZER* 240.1 5% USV 96.8 8%
14 GLENMARK PHARMA 220.2 5% ALKEM* 91.4 7%
15 JANSSEN 195.4 11 % IPCA LABS 89.1 18 %
16 USV 177.9 4% ARISTO PHARMA* 79.7 9%
17 MACLEODS PHARMA 154.8 9% SANOFI* 73.6 9%
18 IPCA LABS 143.6 11 % MICRO LABS* 72.3 4%
19 ASTRAZENECA 137.7 38 % EMCURE* 68.7 8%
20 MICRO LABS* 136.7 -4 % PFIZER* 64.5 2%
Himachal Pradesh J&K Punjab
Rank
Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 CIPLA 67.4 3% SUN* 206.4 10 % CIPLA 745.5 10 %
2 MACLEODS PHARMA 32.1 17 % INTAS PHARMA* 199.0 8% SUN* 518.4 7%
3 ABBOTT* 30.9 11 % CIPLA 170.4 13 % ABBOTT* 516.9 12 %
4 INTAS PHARMA* 28.9 2% ABBOTT* 155.4 7% MICRO LABS* 267.6 3%
5 ZYDUS CADILA* 27.8 25 % LUPIN LIMITED 138.4 16 % LUPIN LIMITED 247.3 3%
6 IPCA LABS 27.8 7% ARISTO PHARMA* 116.7 8% INTAS PHARMA* 244.8 15 %
7 SUN* 27.6 -4 % MACLEODS PHARMA 89.9 3% GLAXOSMITHKLINE* 237.2 3%
8 USV 26.1 3% DR REDDYS LABS 84.9 17 % ZYDUS CADILA* 222.9 14 %
9 LUPIN LIMITED 24.6 12 % ERIS LIFESCIENCES* 84.7 28 % MACLEODS PHARMA 214.7 5%
10 MANKIND 23.8 9% ZYDUS CADILA* 77.5 4% MANKIND 212.8 5%
11 ARISTO PHARMA* 23.3 16 % IPCA LABS 74.8 2% TORRENT PHARMA* 197.4 13 %
12 EMCURE* 19.4 5% TORRENT PHARMA* 67.7 -1 % DR REDDYS LABS 192.2 14 %
13 GLAXOSMITHKLINE* 19.0 6% GLAXOSMITHKLINE* 66.2 2% GLENMARK PHARMA 169.1 14 %
14 GLENMARK PHARMA 16.3 8% ALEMBIC 60.7 2% IPCA LABS 142.7 25 %
15 TORRENT PHARMA* 12.7 27 % GLENMARK PHARMA 57.9 -1 % USV 139.1 13 %
16 BDF 12.2 -32 % EMCURE* 56.6 2% PFIZER* 132.8 7%
17 PFIZER* 10.5 17 % MANKIND 53.8 2% AAREEN HEALTHCARE 119.1 22 %
18 HIMALAYA DRUG 8.8 13 % ALKEM* 46.1 2% EMCURE* 112.3 18 %
19 DABUR INDIA 8.5 -11 % PFIZER* 38.1 3% ARISTO PHARMA* 112.2 6%
20 MEYER ORGANICS 8.5 11 % MICRO LABS* 37.1 5% ALKEM* 107.1 10 %
Rajasthan Uttar Pradesh Uttarakhand
Rank Growth Growth Growth
Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 SUN* 753.9 4% MANKIND 2,258.2 7% MANKIND 100.5 9%
2 CIPLA 581.0 5% CIPLA 1,507.3 12 % MACLEODS PHARMA 93.6 9%
3 MACLEODS PHARMA 495.6 2% ABBOTT* 1,435.9 5% CIPLA 86.4 -1 %
4 ABBOTT* 480.4 5% SUN* 1,155.3 10 % ABBOTT* 84.8 8%
5 INTAS PHARMA* 393.3 4% ALKEM* 1,123.8 7% SUN* 77.0 -3 %
6 ALKEM* 347.7 6% MACLEODS PHARMA 1,039.1 12 % LUPIN LIMITED 74.2 11 %
7 MANKIND 342.8 4% ARISTO PHARMA* 1,033.9 11 % MICRO LABS* 62.2 2%
8 TORRENT PHARMA* 335.7 8% LUPIN LIMITED 847.9 8% INTAS PHARMA* 58.1 12 %
9 ARISTO PHARMA* 326.8 7% ZYDUS CADILA* 709.1 6% GLAXOSMITHKLINE* 55.6 -6 %
10 ZYDUS CADILA* 298.3 3% GLAXOSMITHKLINE* 708.8 -2 % GLENMARK PHARMA 52.9 12 %
11 LUPIN LIMITED 280.0 4% INTAS PHARMA* 690.8 8% ARISTO PHARMA* 50.5 6%
12 DR REDDYS LABS 236.5 10 % TORRENT PHARMA* 677.6 9% ALKEM* 48.7 8%
13 GLAXOSMITHKLINE* 205.1 3% IPCA LABS 659.7 25 % DR REDDYS LABS 48.1 20 %
14 IPCA LABS 202.6 12 % DR REDDYS LABS 629.5 21 % TORRENT PHARMA* 43.7 -7 %
15 EMCURE* 142.3 5% FDC 550.4 14 % IPCA LABS 43.5 25 %
16 GLENMARK PHARMA 132.8 1% MICRO LABS* 497.5 3% ERIS LIFESCIENCES* 32.8 -0 %
17 MICRO LABS* 127.3 -5 % EMCURE* 470.4 10 % HIMALAYA DRUG 31.5 8%
18 JB PHARMA* 121.8 8% GLENMARK PHARMA 406.7 13 % ZYDUS CADILA* 27.4 0%
19 PFIZER* 106.7 -0 % PFIZER* 378.6 -10 % SANOFI* 22.8 16 %
20 FDC 106.7 5% JB PHARMA* 374.6 15 % PFIZER* 20.3 10 %

Source: IQVIA TSA Dataset July'2024 14

 North Zone Top Brands- MAT
July’24
Delhi Haryana Himachal Pradesh
Rank Value'C Growth Value'C Growth Value'C Growth
Brand Company Brand Company Brand Company
r % r % r %
1 ULTRACET JANSSEN 79.2 1% FORACORT CIPLA 37.2 12 % HANSAPLAST BDF 12.1 -32 %
2 AUGMENTIN GSK* 71.4 12 % LIV-52 HIMALAYA 30.4 32 % NEW SARIDON BAYER 5.2 0%
3 REVITAL H SUN* 60.2 16 % AUGMENTIN GSK* 25.3 -9 % METPURE-XL EMCURE* 5.0 -3 %
4 VOLINI SUN* 59.6 -1 % UDILIV ABBOTT* 23.0 33 % BECOSULES PFIZER* 4.4 25 %
5 LIV-52 HIMALAYA 57.6 44 % RYZODEG ABBOTT* 19.9 19 % FORACORT CIPLA 4.2 20 %
6 UDILIV ABBOTT* 57.3 26 % MANFORCE MANKIND 18.0 10 % LIV-52 HIMALAYA 4.0 21 %
7 REMICADE JANSSEN 55.0 24 % GLYCOMET-GP USV 17.6 -3 % THYROX MACLEODS 3.9 26 %
8 THYRONORM ABBOTT* 49.6 20 % DUOLIN CIPLA 17.1 12 % GLYCOMET-GP U S V 3.6 4%
9 PREVENAR-13 PFIZER* 49.1 25 % GLUCONORM-G LUPIN 16.8 13 % MANFORCE MANKIND 3.5 25 %
10 JARDIANCE BOEHRINGER 48.9 23 % LANTUS SANOFI* 16.6 21 % URIMAX-D CIPLA 3.3 32 %
11 RYBELSUS ABBOTT* 48.1 103 % BUDECORT CIPLA 16.6 -5 % AUGMENTIN GSK* 2.8 -14 %
12 ZAXTER ALKEM* 46.0 6% RYBELSUS ABBOTT* 16.1 93 % DUOLIN CIPLA 2.8 0%
13 ZAVICEFTA PFIZER* 44.8 301 % MONTAIR-LC CIPLA 15.6 -0 % ZERODOL-SP IPCA 2.7 3%
14 ROSUVAS SUN* 42.8 74 % BETADINE WIN MEDI. 14.8 -7 % ROSUVAS SUN* 2.7 49 %
15 CYRAMZA ELI LILLY 42.3 40 % FOLISURGE INTAS * 12.8 38 % CETAPHIL GALDERMA 2.5 112 %
16 LEVERA INTAS * 41.9 58 % MONOCEF ARISTO* 12.8 4% JALRA-M USV 2.5 -23 %
17 FORACORT CIPLA 40.4 11 % ENCLEX CIPLA 12.7 26 % GLUCO ONE MOREPEN 2.4 20 %
18 TAGRISSO ASTRAZENE. 36.0 81 % ZIFI FDC 12.6 -6 % OROFER FCM EMCURE* 2.3 -4 %
19 RYZODEG ABBOTT* 34.6 14 % ROSUVAS SUN* 12.6 12 % FLAVEDON SERVIER 2.3 3%
20 DUPHASTON ABBOTT* 34.4 105 % AEROCORT CIPLA 12.1 37 % AMOXYCLAV ABBOTT* 2.2 81 %
J&K Punjab Rajasthan
Rank Growt Growth Growth
Brand Company Value'Cr Brand Company Value'Cr Brand Company Value'Cr
h% % %
1 NEW SARIDON BAYER 22.8 >500 % LIV-52 HIMALAYA 47.0 40 % MONOCEF ARISTO* 69.6 7%
2 HUMINSULIN LUPIN 17.0 7 % UDILIV ABBOTT* 44.8 22 % FORACORT CIPLA 56.0 16 %
3 UDILIV ABBOTT* 16.7 29 % FORACORT CIPLA 39.8 5% MANFORCE MANKIND 38.8 15 %
4 PANTOP ARISTO* 16.2 7 % FLEXBUMIN TAKEDA 36.3 >500 % AUGMENTIN GSK* 35.6 2%
5 AUGMENTIN GSK* 14.6 -10 % AUGMENTIN GSK* 36.2 -7 % AMICIN ZYDUS* 27.8 7%
6 THYRONORM ABBOTT* 14.5 8 % SUPRADYN BAYER 30.8 8% LIV-52 HIMALAYA 25.4 8%
7 MONOCEF-SB ARISTO* 13.1 27 % BUDECORT CIPLA 28.8 17 % BETNOVATE-N GSK* 25.2 7%
8 PANTOP-D ARISTO* 12.2 2 % MYHEP ALL MYLAN 28.4 -15 % LANTUS SANOFI* 25.1 6%
9 MONOCEF ARISTO* 8.9 4 % DYTOR CIPLA 28.1 27 % LEVIPIL SUN* 24.6 28 %
10 TELMA-AM GLENMARK 8.9 17 % BECOZYM-C FORT BAYER 25.9 4% DEXORANGE FRANCO 23.5 -12 %
11 DART OLD JUGGAT 8.7 15 % BECOSULES PFIZER* 24.7 18 % RYZODEG ABBOTT* 23.1 30 %
12 ZERODOL-SP IPCA 8.6 11 % ELORES CIPLA 24.4 64 % ZERODOL-SP IPCA 22.8 27 %
13 GLUCONORM-G LUPIN 8.6 29 % ACILOC CADILA 24.3 22 % DUOLIN CIPLA 22.8 9%
14 INFLUVAC ABBOTT* 8.1 -20 % SOFOCURE EMCURE 23.8 65 % MONTAIR-LC CIPLA 21.9 -9 %
15 LIV-52 HIMALAYA 8.1 30 % GLYCOMET-GP USV 23.4 5% RANTAC JB * 21.1 9%
16 CYRA-D SYSTOPIC 8.0 6 % MIXTARD ABBOTT* 22.9 -6 % THYRONORM ABBOTT* 21.1 8%
17 URISPAS MARTIN H. 7.9 -1 % ECOSPRIN-AV USV 22.6 11 % PANTOCID-D SUN* 20.8 -5 %
18 MANFORCE MANKIND 7.8 2 % MONTAIR-LC CIPLA 22.2 -4 % GEMER SUN* 20.4 1%
19 ROSUVAS SUN* 7.8 1 % MANFORCE MANKIND 21.6 11 % BUDECORT CIPLA 20.3 8%
20 BUDAMATE LUPIN 7.6 49 % INFANRIX HEXA GSK* 21.5 13 % MONOCEF-SB ARISTO* 20.2 4%
Uttar Pradesh Uttarakhand
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MONOCEF ARISTO* 188.6 16 % LIV-52 HIMALAYA 14.0 14 %
2 UNWANTED-KIT MANKIND 151.9 6% AUGMENTIN GSK* 11.3 -10 %
3 LIV-52 HIMALAYA 149.1 23 % MANFORCE MANKIND 8.8 9%
4 MANFORCE MANKIND 134.6 12 % BETADINE WIN MEDI. 8.4 -7 %
5 ACILOC CADILA 130.3 4% FORACORT CIPLA 7.4 17 %
6 ZIFI FDC 115.9 5% ACILOC CADILA 5.9 4%
7 FORACORT CIPLA 109.9 10 % DOLO MICRO* 5.7 -9 %
8 ELECTRAL FDC 109.7 34 % LEVERA INTAS * 5.2 11 %
9 MOXIKIND-CV MANKIND 105.3 11 % JOHNSON BABY J&J 5.0 72 %
10 AUGMENTIN GSK* 102.4 -2 % LANTUS SANOFI* 5.0 8%
11 ZERODOL-SP IPCA 101.3 26 % JANUMET MSD* 5.0 6%
12 DEXORANGE FRANCO 100.1 -4 % MONOCEF ARISTO* 4.9 -3 %
13 MIKACIN ARISTO* 95.6 8% HEPA-MERZ WIN MEDI. 4.9 34 %
14 BETADINE WIN MEDI. 94.0 11 % THYRONORM ABBOTT* 4.7 10 %
15 CALPOL GSK* 91.3 -2 % CALPOL GSK* 4.7 -12 %
16 METROGYL JB * 77.6 7% BETNOVATE-N GSK* 4.5 -14 %
17 GUDCEF MANKIND 74.1 10 % TELMA-AM GLENMARK 4.5 15 %
18 UDILIV ABBOTT* 72.9 28 % CANDID GLENMARK 4.5 73 %
19 DUOLIN CIPLA 71.4 24 % TELMA GLENMARK 4.4 22 %
20 BETNOVATE-N GSK* 67.0 -12 % ZAXTER ALKEM* 4.4 9%

Source: IQVIA TSA Dataset July'2024 15

West Zone Top Companies- MAT
July’24
Goa Gujarat
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 52.9 9% ABBOTT* 625.7 11 %
2 ABBOTT* 38.9 3% CIPLA 616.1 4%
3 CIPLA 29.8 -6 % SUN* 495.8 11 %
4 ZYDUS CADILA* 29.7 -9 % TORRENT PHARMA* 489.7 7%
5 GLAXOSMITHKLINE* 28.3 30 % ZYDUS CADILA* 402.4 15 %
6 EMCURE* 23.2 7% INTAS PHARMA* 345.2 4%
7 LUPIN LIMITED 21.8 2% MANKIND 340.4 5%
8 TORRENT PHARMA* 16.4 19 % UNISON PHARMA 316.2 15 %
9 MANKIND 16.4 -13 % DR REDDYS LABS 240.8 13 %
10 ARISTO PHARMA* 15.9 12 % EMCURE* 208.8 8%
11 MACLEODS PHARMA 15.3 7% CORONA REMEDIES 208.3 10 %
12 DR REDDYS LABS 14.4 11 % LUPIN LIMITED 197.9 8%
13 GLENMARK PHARMA 14.0 14 % GLAXOSMITHKLINE* 196.3 0%
14 MICRO LABS* 13.6 43 % IPCA LABS 188.0 10 %
15 FRANCO INDIAN 12.6 55 % ALKEM* 185.0 3%
16 INDOCO* 12.3 -16 % USV 184.1 -2 %
17 ALEMBIC 12.3 -8 % ARISTO PHARMA* 183.5 18 %
18 USV 11.7 -4 % MACLEODS PHARMA 176.7 9%
19 ERIS LIFESCIENCES* 10.8 8% JB PHARMA* 138.5 13 %
20 WALLACE* 10.4 -1 % PFIZER* 127.5 11 %

Madhya Pradesh Maharashtra Mumbai

Growth Growth Growth
Rank Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 MANKIND 602.7 11 % CIPLA 1,126.8 6% ABBOTT* 708.8 19 %
2 ABBOTT* 563.7 12 % SUN* 1,056.8 13 % SUN* 580.1 1%
3 ARISTO PHARMA* 501.6 7% ABBOTT* 1,022.3 9% CIPLA 487.5 -5 %
4 SUN* 490.2 8% MANKIND 977.1 13 % TORRENT* 449.4 10 %
5 MACLEODS 446.5 12 % EMCURE* 844.4 10 % INTAS* 420.6 9%
6 LUPIN LIMITED 365.4 15 % ALKEM* 694.5 8% MANKIND 369.7 22 %
7 ALKEM* 356.3 10 % MACLEODS 691.7 11 % DRL 341.4 1%
8 CIPLA 343.6 11 % DRL 646.6 12 % EMCURE* 341.0 -0 %
9 INTAS PHARMA* 336.2 15 % INTAS PHARMA* 602.6 17 % USV 252.5 10 %
10 ZYDUS CADILA* 290.1 8% FDC 541.9 10 % ALKEM* 226.6 6%
11 DR REDDYS LABS 223.5 11 % LUPIN LIMITED 524.7 5% LUPIN 224.5 11 %
12 GSK* 199.8 2% TORRENT * 476.0 8% GLENMARK 223.6 2%
13 FDC 198.3 10 % ZYDUS CADILA* 433.9 11 % GSK* 221.3 -10 %
14 TORRENT* 184.7 17 % IPCA LABS 412.9 10 % MACLEODS 207.7 8%
15 IPCA LABS 172.5 15 % GLENMARK 375.9 16 % IPCA LABS 178.6 20 %
16 EMCURE* 160.3 2% USV 369.0 3% PFIZER* 172.8 -6 %
17 U S V 148.5 12 % GSK* 366.3 6% ZYDUS CADILA* 135.0 1%
18 ALEMBIC 143.3 7% ARISTO PHARMA* 319.5 9% SANOFI* 121.4 -6 %
19 LA RENON 124.6 24 % ALEMBIC 291.8 -0 % RELIANCE LIFE. 105.4 70 %
20 MEDLEY PHARMA 123.8 10 % INDOCO* 262.1 2% ERIS LIFE.* 101.6 8%

Source: IQVIA TSA Dataset July'2024 16

West Zone Top Brands- MAT
July’24
Goa Gujarat Madhya Pradesh
Ran
k Value' Growth Value' Growth Value Growth
Brand Company Brand Company Brand Company
Cr % Cr % 'Cr %
1 AUGMENTIN GSK* 6.4 54 % FORACORT CIPLA 49.4 24 % MONOCEF ARISTO* 61.5 11 %

2 ELECTRAL FDC 3.9 27 % VIVITRA ZYDUS* 48.0 42 % DEXORANGE FRANCO 51.2 8%

3 DEXOLAC NUTRICIA 3.7 -14 % ZOSTUM EMCURE* 41.9 21 % ACILOC CADILA 48.0 11 %

4 OROFER-XT EMCURE* 3.5 41 % LANTUS SANOFI* 33.9 9% MANFORCE MANKIND 42.3 5%

5 SINAREST NEW CENTAUR 3.2 15 % PREVENAR-13 PFIZER* 32.7 13 % ELECTRAL FDC 39.3 3%

6 THROMBOPHOB ZYDUS* 2.9 22 % AUGMENTIN GSK* 31.8 -1 % MONTAZ ARISTO* 31.8 7%

7 BETADINE WIN MEDI. 2.5 -9 % ECOSPRIN-AV USV 30.8 -1 % ZIFI FDC 30.3 2%

8 CILACAR JB * 2.5 3% MIXTARD ABBOTT* 30.7 1% LIV-52 HIMALAYA 29.1 19 %

9 GLYCIPHAGE FRANCO 2.4 64 % MERO ARISTO* 30.6 47 % ZINCOVIT APEX 26.8 9%

10 VOLINI SUN* 2.2 -6 % RYZODEG ABBOTT* 29.5 36 % AUGMENTIN GSK* 26.6 3%

WATERBURYS PIRAMAL
11 2.1 155 % DUOLIN CIPLA 29.0 -4 % PANTOP ARISTO* 26.4 21 %
COMPOUN HEALTH.
12 DOLO MICRO* 2.0 8% DUPHASTON ABBOTT* 28.8 11 % MIKACIN ARISTO* 26.3 2%

13 CEFTUM GSK* 1.9 3% INFLUVAC ABBOTT* 28.7 3% GLYCOMET-GP U S V 26.2 6%

14 SENSODYNE GSK* 1.9 55 % RYBELSUS ABBOTT* 27.2 78 % R.B.TONE MEDLEY 26.1 30 %

15 ATORVA ZYDUS* 1.9 -16 % CYRAMZA ELI LILLY 26.8 128 % CALPOL GSK* 25.7 5%

16 D-PROTIN BRITISH BIO. 1.9 75 % GLYCOMET-GP U S V 24.2 -13 % FORACORT CIPLA 25.3 22 %

17 T-BACT GSK* 1.8 70 % BUDECORT CIPLA 24.0 -5 % LANTUS SANOFI* 24.3 -3 %

RELIANCE
18 FORACORT CIPLA 1.8 9% ALBUREL 23.7 -6 % TAXIM ALKEM* 24.2 14 %
LIFE.
19 DEXORANGE FRANCO 1.8 27 % INFANRIX HEXA GSK* 23.7 18 % MONOCEF-O ARISTO* 22.4 1%

20 GLYCOMET-GP USV 1.7 -8 % ZIFI FDC 23.2 2% MEGA-CV ARISTO* 20.8 1%

Maharashtra Mumbai
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %

1 HANSAPLAST BDF 106.1 33 % IMMUNOREL RELIANCE LIFE. 68.4 104 %

2 ENERZAL FDC 96.4 27 % AUGMENTIN GSK* 50.9 -9 %
3 CLAVAM ALKEM* 75.9 2% FORACORT CIPLA 41.5 11 %
4 GLYCOMET-GP USV 66.3 -1 % SHELCAL XT TORRENT * 36.1 32 %
5 FORACORT CIPLA 63.1 14 % RYBELSUS ABBOTT* 35.0 87 %
6 MIXTARD ABBOTT* 56.1 4% RYZODEG ABBOTT* 34.6 10 %
7 ECOSPRIN-AV USV 54.1 9% ROSUVAS SUN* 33.5 57 %
8 AUGMENTIN GSK* 52.3 7% GLYCOMET-GP USV 32.3 5%
9 TELMA GLENMARK 49.7 36 % SHELCAL TORRENT * 30.8 -3 %
10 ZERODOL-SP IPCA 48.8 20 % PAN-D ALKEM* 30.4 30 %
11 ZIFI FDC 48.5 -2 % REJOINT NEW ABBOTT* 29.7 287 %
12 MOXIKIND-CV MANKIND 47.8 11 % ALBUREL RELIANCE LIFE. 29.3 31 %
13 DUOLIN CIPLA 46.2 8% OROFER-XT EMCURE* 28.5 3%
14 PAN ALKEM* 45.9 13 % MIXTARD ABBOTT* 27.8 -14 %
15 ELECTRAL FDC 45.3 11 % LANTUS SANOFI* 27.0 -28 %
16 PAN-D ALKEM* 43.4 29 % NIKORAN TORRENT * 26.9 24 %
17 BETADINE WIN MEDI. 43.3 14 % NOVO RAPID ABBOTT* 26.0 8%
18 RYBELSUS ABBOTT* 40.3 59 % VYMADA NOVARTIS* 25.5 -32 %
19 LANTUS SANOFI* 39.2 11 % MINIPRESS-XL PFIZER* 24.9 7%
20 DUPHASTON ABBOTT* 39.1 12 % TELMA GLENMARK 24.0 -4 %

Source: IQVIA TSA Dataset July'2024 17

South Zone Top Companies- MAT
July’24
Andhra Pradesh Karnataka Kerala
Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 818.2 6% SUN* 1,066.9 14 % SUN* 1,403.3 4%
2 ABBOTT* 539.8 7% ABBOTT* 753.0 1% ABBOTT* 830.5 8%
3 MANKIND 417.6 0% CIPLA 600.1 1% CIPLA 767.4 5%
4 CIPLA 393.8 14 % MANKIND 598.7 6% ZYDUS CADILA* 459.7 2%
5 DR REDDYS LABS 375.9 11 % MICRO LABS* 525.0 3% TORRENT PHARMA* 457.7 10 %
6 ARISTO PHARMA* 346.7 -0 % USV 469.1 6% LUPIN LIMITED 343.7 4%
7 INTAS PHARMA* 295.6 8% TORRENT PHARMA* 466.1 3% INTAS PHARMA* 329.8 15 %
8 ALKEM* 282.3 1% ALKEM* 417.8 -0 % GLENMARK PHARMA 302.0 15 %
9 LUPIN LIMITED 279.7 3% DR REDDYS LABS 377.9 -7 % MACLEODS PHARMA 294.6 2%
10 MACLEODS PHARMA 272.1 2% LUPIN LIMITED 375.4 1% USV 287.0 19 %
11 TORRENT PHARMA* 266.5 -1 % ZYDUS CADILA* 354.3 2% DR REDDYS LABS 271.3 7%
12 ZYDUS CADILA* 224.6 6% EMCURE* 294.6 -3 % ARISTO PHARMA* 261.7 6%
13 U S V 199.1 -2 % GLENMARK PHARMA 289.6 24 % GLAXOSMITHKLINE* 227.5 -4 %
14 GLENMARK PHARMA 148.7 -2 % GLAXOSMITHKLINE* 272.9 2% MICRO LABS* 216.3 -1 %
15 EMCURE* 130.8 -2 % MACLEODS PHARMA 263.8 6% MANKIND 198.3 14 %
16 IPCA LABS 125.5 7% IPCA LABS 245.4 13 % JB PHARMA* 190.2 1%
17 GLAXOSMITHKLINE* 115.8 -8 % INTAS PHARMA* 238.3 1% IPCA LABS 170.5 18 %
18 PFIZER* 109.4 -5 % ARISTO PHARMA* 209.7 12 % ERIS LIFESCIENCES* 159.0 7%
19 MICRO LABS* 100.8 -5 % PFIZER* 207.4 -4 % PFIZER* 143.0 -5 %
20 JB PHARMA* 98.5 4% JANSSEN 191.8 47 % BLUE CROSS 132.9 1%

Tamilnadu Telangana Chennai

Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %

1 SUN* 1,345.9 8% ABBOTT* 827.8 8% SUN* 439.6 12 %

2 CIPLA 831.4 14 % SUN* 744.8 7% ABBOTT* 311.2 8%

3 ABBOTT* 728.8 4% INTAS PHARMA* 556.6 13 % DR REDDYS LABS 231.3 4%

4 MANKIND 452.8 8% CIPLA 508.4 15 % INTAS PHARMA* 193.3 22 %

5 TORRENT PHARMA* 448.4 20 % DR REDDYS LABS 473.2 12 % TORRENT PHARMA* 176.1 6%

6 LUPIN LIMITED 410.9 8% MANKIND 444.8 10 % LUPIN LIMITED 175.8 1%

7 ZYDUS CADILA* 349.0 5% LUPIN LIMITED 427.0 12 % CIPLA 166.6 -6 %

8 GLAXOSMITHKLINE* 309.1 -2 % TORRENT PHARMA* 418.7 1% USV 164.2 10 %

9 DR REDDYS LABS 294.5 10 % ALKEM* 395.1 5% MANKIND 136.3 7%

10 ALKEM* 252.1 15 % GLENMARK PHARMA 392.6 24 % GLENMARK PHARMA 127.5 1%

GLENMARK
11 249.6 15 % USV 340.9 1% ALKEM* 117.8 4%
PHARMA
12 FOURRTS INDIA 243.0 12 % EMCURE* 338.9 24 % ZYDUS CADILA* 117.6 13 %

13 MICRO LABS* 233.1 1% ARISTO PHARMA* 264.7 10 % IPCA LABS 116.9 21 %

14 PFIZER* 227.5 -2 % MACLEODS PHARMA 236.1 1% MICRO LABS* 115.0 3%

LA RENON
15 U S V 225.6 14 % ZYDUS CADILA* 227.8 7% 109.9 15 %
HEALTHCA.
16 INTAS PHARMA* 201.5 20 % IPCA LABS 201.4 22 % EMCURE* 103.5 6%

17 EMCURE* 198.4 2% PFIZER* 192.3 -10 % GLAXOSMITHKLINE* 102.9 8%

ERIS
18 193.6 14 % GLAXOSMITHKLINE* 185.1 -7 % PFIZER* 81.3 -12 %
LIFESCIENCES*
MERCK
19 ARISTO PHARMA* 176.7 10 % SANOFI* 185.0 7% 75.7 92 %
SPECIALITIES
HETERO
20 IPCA LABS 157.1 22 % 175.5 -1 % ERIS LIFESCIENCES* 71.6 6%
HEALTHCARE*

Source: IQVIA TSA Dataset July'2024 18

 South Zone Top Brands- MAT
July’24
Andhra Pradesh Karnataka Kerala
Rank
Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
1 GLYCOMET-GP U S V 53.6 -3 % GLYCOMET-GP U S V 116.0 7% MIXTARD ABBOTT* 112.6 3%

2 MIXTARD ABBOTT* 48.3 -0 % MIXTARD ABBOTT* 74.5 -14 % FORACORT CIPLA 88.8 14 %

3 GEMER SUN* 40.6 -1 % ULTRACET JANSSEN 62.8 12 % CILACAR JB * 76.1 9%

4 PANTOP ARISTO* 35.5 6% DARZALEX JANSSEN 59.4 142 % THYRONORM ABBOTT* 66.8 5%

5 ZINCOVIT APEX 34.5 -0 % DOLO MICRO* 56.7 -3 % GLYCOMET-GPU S V 56.4 8%

6 THYRONORM ABBOTT* 33.1 17 % THYRONORM ABBOTT* 54.9 2% AUGMENTIN GSK* 50.1 5%

7 MONOCEF ARISTO* 30.1 -2 % AUGMENTIN GSK* 49.6 12 % SEROFLO CIPLA 48.2 8%

8 FORACORT CIPLA 27.7 29 % LEVIPIL SUN* 46.1 19 % CONCOR MERCK 46.4 26 %

9 ROSUVAS SUN* 27.1 18 % VOLINI SUN* 38.5 -9 % PANTOCID SUN* 45.6 -7 %

10 BOSENTAS CIPLA 27.1 304 % ZERODOL-SP IPCA 37.5 18 % PANTOP ARISTO* 42.2 6%

11 DOLO MICRO* 26.9 -20 % SHELCAL TORRENT * 35.1 17 % MOXCLAV SUN* 41.6 -15 %

12 MYFAIR ZEE 24.8 4% FORACORT CIPLA 34.9 3% TELMA GLENMARK 38.9 25 %

GLYCOMET
13 DUOLIN CIPLA 23.6 23 % USV 34.7 -1 % ROSUVAS SUN* 38.8 2%
TRIO
14 TELMA-H GLENMARK 22.8 19 % ECOSPRIN-AV USV 33.6 -2 % LANTUS SANOFI* 37.4 -8 %

15 MONOCEF-SB ARISTO* 21.8 5% RYZODEG ABBOTT* 32.5 -10 % BUDECORT CIPLA 32.2 16 %

16 ZORYL-M INTAS * 21.2 -4 % PAN ALKEM* 32.0 12 % SHELCAL TORRENT * 32.1 -6 %

17 LEVIPIL SUN* 20.9 15 % MOXIKIND-CV MANKIND 31.9 14 % JANUMET MSD* 31.5 0%

18 BUDECORT CIPLA 20.6 9% DUPHASTON ABBOTT* 31.9 10 % NOVOMIX ABBOTT* 30.1 -9 %

19 AMLOKIND-AT MANKIND 19.7 10 % CILACAR JB * 31.7 3% LEVIPIL SUN* 29.5 2%

20 BEPLEX FORTE LUPIN 19.6 40 % BUDECORT CIPLA 30.1 18 % UDILIV ABBOTT* 29.5 29 %

Tamilnadu Telangana Chennai

Rank
Value Growth Value' Growth Value Growth
Brand Company Brand Company Brand Company
'Cr % Cr % 'Cr %
1 MIXTARD ABBOTT* 81.7 -12 % TAFFIC HETERO* 102.3 -1 % ERBITUX MERCK 55.0 152 %

2 TEDIBAR TORRENT * 57.4 35 % TELMA-H GLENMARK 80.4 59 % MIXTARD ABBOTT* 31.8 1%

3 FORACORT CIPLA 53.8 18 % GLYCOMET-GP U S V 79.7 -2 % FOLISURGE INTAS * 28.7 40 %

4 ROSUVAS SUN* 50.5 17 % MIXTARD ABBOTT* 71.8 -11 % GLYCOMET-GP U S V 28.0 -3 %

GLYCOMET-
5 USV 49.6 5% THYRONORM ABBOTT* 57.9 -2 % RYZODEG ABBOTT* 26.0 26 %
GP
RENERVE RELIANCE
6 ERIS* 48.6 12 % ALBUREL 57.1 75 % JANUMET MSD* 25.6 19 %
PLUS LIFE.
7 AUGMENTIN GSK* 48.2 4% CLEXANE SANOFI* 55.8 114 % PAN ALKEM* 24.3 4%

8 GEMER SUN* 44.9 1% LANTUS SANOFI* 52.5 21 % NOVOMIX ABBOTT* 20.2 -6 %

9 LEVIPIL SUN* 41.3 -6 % TELMA GLENMARK 51.1 20 % PREVENAR-13 PFIZER* 20.1 16 %

10 T-BACT GSK* 40.3 -9 % RYZODEG ABBOTT* 48.5 15 % JARDIANCE BOEHRINGER 19.9 27 %

11 PAN ALKEM* 36.8 30 % ERBITUX MERCK 44.5 183 % LANTUS SANOFI* 19.4 13 %

12 ZINCOVIT APEX 35.1 -2 % MEROPLAN ABBOTT* 44.0 2% AUGMENTIN GSK* 18.0 19 %

13 VOLINI SUN* 32.5 2% DOLO MICRO* 42.6 -11 % DUPHASTON ABBOTT* 17.4 -13 %

14 ASTHALIN CIPLA 32.2 9% NOVOMIX ABBOTT* 40.0 -19 % MABTAS INTAS * 17.2 57 %

15 ELTROXIN GSK* 30.8 -4 % OPDYTA BMS 36.3 52 % TELMA GLENMARK 16.5 30 %

16 SUSTEN SUN* 30.3 4% CLAVAM ALKEM* 33.1 2% AZITHRAL ALEMBIC 16.1 -14 %

17 SUCRAFIL O FOURRTS 29.6 16 % ZORYL-M INTAS * 33.0 6% CANMAB BIOCON 15.6 37 %

RELIANCE
18 PREVENAR-13 PFIZER* 29.1 17 % LEVIPIL SUN* 32.5 8% RITUXIREL 14.0 255 %
LIFE.
19 TELMA-H GLENMARK 28.8 35 % DUPHASTON ABBOTT* 32.0 19 % MONTEK-LC SUN* 13.9 31 %
GLYCOMET
20 GELUSIL-MPS PFIZER* 28.8 17 % USV 31.3 -7 % RENERVE PLUS ERIS* 13.8 -4 %
TRIO

Source: IQVIA TSA Dataset July'2024 19